85.95

3.38% 2.77

Ionis Pharmaceuticals Inc (IONS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$83.18

Offen:

$84.42

24-Stunden-Volumen:

1.66M

Relative Volume:

0.92

Marktkapitalisierung:

$14.21B

Einnahmen:

$1.06B

Nettoeinkommen (Verlust:

$-326.58M

KGV:

-40.89

EPS:

-2.1022

Netto-Cashflow:

$-977.73M

1W Leistung:

+8.45%

1M Leistung:

+15.45%

6M Leistung:

+3.39%

1J Leistung:

+105.82%

1-Tages-Spanne:

$82.95

$86.67

1-Wochen-Bereich:

$77.95

$86.67

52-Wochen-Spanne:

$40.03

$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Firmenname

Ionis Pharmaceuticals Inc

Sektor

Healthcare (1100)

Branche

Biotechnology (615)

Telefon

(760) 931-9200

Adresse

2855 GAZELLE COURT, CARLSBAD, CA

Mitarbeiter

1,402

Twitter

@ionispharma

Nächster Verdiensttermin

2026-07-29

Neueste SEC-Einreichungen

IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IONS Ionis Pharmaceuticals Inc	85.95	13.52B	1.06B	-326.58M	-977.73M	-2.1022
VRTX Vertex Pharmaceuticals Inc	524.31	134.02B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.45	68.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	921.42	58.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	320.25	41.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	191.81	40.23B	742.00K	-1.37B	-1.07B	-7.0731

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-21	Eingeleitet	Canaccord Genuity	Buy
2026-04-10	Fortgesetzt	Raymond James	Outperform
2026-01-28	Fortgesetzt	Barclays	Overweight
2025-10-08	Hochstufung	JP Morgan	Neutral → Overweight
2025-09-26	Hochstufung	Goldman	Sell → Neutral
2025-09-03	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2025-07-31	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-07-01	Hochstufung	Barclays	Equal Weight → Overweight
2025-04-07	Eingeleitet	H.C. Wainwright	Buy
2025-03-31	Eingeleitet	Redburn Atlantic	Neutral
2024-08-02	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-07-24	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-07-16	Fortgesetzt	Jefferies	Buy
2024-06-14	Hochstufung	Bernstein	Underperform → Mkt Perform
2024-04-10	Hochstufung	Wolfe Research	Peer Perform → Outperform
2024-01-02	Hochstufung	BofA Securities	Neutral → Buy
2023-10-23	Hochstufung	BofA Securities	Underperform → Neutral
2023-09-29	Eingeleitet	Raymond James	Strong Buy
2023-07-31	Hochstufung	Citigroup	Neutral → Buy
2023-06-07	Fortgesetzt	Piper Sandler	Overweight
2023-05-04	Hochstufung	Citigroup	Sell → Neutral
2023-03-21	Eingeleitet	Bernstein	Underperform
2022-12-21	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-09-09	Fortgesetzt	Morgan Stanley	Overweight
2022-07-18	Fortgesetzt	Oppenheimer	Outperform
2022-03-31	Fortgesetzt	Piper Sandler	Overweight
2022-03-01	Eingeleitet	Citigroup	Sell
2022-03-01	Eingeleitet	Guggenheim	Buy
2022-02-01	Herabstufung	BofA Securities	Buy → Underperform
2021-12-14	Hochstufung	William Blair	Mkt Perform → Outperform
2021-05-07	Hochstufung	UBS	Sell → Neutral
2021-03-01	Hochstufung	Barclays	Underweight → Equal Weight
2020-12-16	Eingeleitet	UBS	Sell
2020-12-15	Hochstufung	Cowen	Market Perform → Outperform
2020-09-14	Fortgesetzt	JP Morgan	Neutral
2020-09-02	Eingeleitet	The Benchmark Company	Hold
2020-06-01	Fortgesetzt	Oppenheimer	Outperform
2020-05-13	Eingeleitet	RBC Capital Mkts	Outperform
2020-03-05	Eingeleitet	Citigroup	Buy
2019-12-13	Eingeleitet	Oppenheimer	Outperform
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-11-07	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2019-09-10	Hochstufung	Bernstein	Mkt Perform → Outperform
2018-08-08	Bestätigt	Stifel	Hold
2018-08-07	Bestätigt	Stifel	Hold
2018-05-08	Herabstufung	Evercore ISI	Outperform → In-line
2017-10-06	Fortgesetzt	Goldman	Sell
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-08-09	Bestätigt	Stifel	Hold
2017-03-10	Herabstufung	Goldman	Neutral → Sell
2016-12-28	Bestätigt	BMO Capital Markets	Outperform
2016-12-27	Bestätigt	Leerink Partners	Mkt Perform

Alle ansehen

Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten

06:42 AM

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.

06:42 AM

05:04 AM

Ionis Pharmaceuticals concludes REVEAL study pivotal cohort enrolment - Clinical Trials Arena

05:04 AM

Jul 06, 2026

Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart.com

Jul 06, 2026

Ionis Pharmaceuticals director Joseph Klein III sells $910k in stock - Investing.com Canada

Jul 06, 2026

Form 4 Ionis Pharmaceuticals Inc For: 6 July By Investing.com - Investing.com Canada

Jul 06, 2026

Ionis Pharmaceuticals Advances Obudanersen for Angelman Syndrome - GuruFocus

Jul 06, 2026

Ionis Pharmaceuticals, Inc. Completes Enrollment in Pivotal Cohort of Phase 3 REVEAL Study Evaluating Obudanersen in Angelman Syndrome - marketscreener.com

Jul 06, 2026

Ionis Pharmaceuticals (IONS) Advances Phase 3 REVEAL Study for A - GuruFocus

Jul 06, 2026

Ionis completes enrollment in Angelman syndrome drug trial By Investing.com - Investing.com Canada

Jul 06, 2026

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome - Business Wire

Jul 06, 2026